MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer.

Autor: Richardsen E; Translational Cancer Research Group, Institute of Medical Biology, UiT The Arctic University of Norway, 9037, Tromsø, Norway. elin-ri@live.no.; Department of Clinical Pathology, University Hospital of North Norway, 9038, Tromsø, Norway. elin-ri@live.no., Andersen S; Translational Cancer Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, 9037, Tromsø, Norway.; Department of Oncology, University Hospital of North Norway, 9038, Tromsø, Norway., Melbø-Jørgensen C; NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Rakaee M; Translational Cancer Research Group, Institute of Medical Biology, UiT The Arctic University of Norway, 9037, Tromsø, Norway., Ness N; Translational Cancer Research Group, Institute of Medical Biology, UiT The Arctic University of Norway, 9037, Tromsø, Norway., Al-Saad S; Translational Cancer Research Group, Institute of Medical Biology, UiT The Arctic University of Norway, 9037, Tromsø, Norway.; Department of Clinical Pathology, University Hospital of North Norway, 9038, Tromsø, Norway., Nordby Y; Translational Cancer Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, 9037, Tromsø, Norway.; Department of Urology, University Hospital of North Norway, 9038, Tromsø, Norway., Pedersen MI; Translational Cancer Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, 9037, Tromsø, Norway., Dønnem T; Translational Cancer Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, 9037, Tromsø, Norway., Bremnes RM; Translational Cancer Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, 9037, Tromsø, Norway.; Department of Oncology, University Hospital of North Norway, 9038, Tromsø, Norway., Busund LT; Translational Cancer Research Group, Institute of Medical Biology, UiT The Arctic University of Norway, 9037, Tromsø, Norway.; Department of Clinical Pathology, University Hospital of North Norway, 9038, Tromsø, Norway.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2019 Jan 23; Vol. 9 (1), pp. 386. Date of Electronic Publication: 2019 Jan 23.
DOI: 10.1038/s41598-018-36854-7
Abstrakt: A large number of miRNAs influence key cellular processes involved in prostate tumorigenesis. Previous studies have demonstrated high expression of miRNAs in human prostate cancer (PC) tissues and cell lines. In previous microarray data, we found miR-141 to be upregulated and miR-145 to be downregulated in PC. In this large PC cohort (n = 535), we explored the prognostic role of miR-141 and miR-145 in PC. Tumor epithelial (TE) and tumor stromal (TS) areas were evaluated separately and combined (TE + TS). In situ hybridization was used to evaluate the expression of the miRNAs. We found that miR-141 (TE) correlated significantly to Gleason score ≥8 (p = 0.040) and large tumor size (≥20 mm, p = 0.025) and miR-141 (TE + TS) to Gleason grade (p = 0.001). MiR-145 correlated to pT-stage (p = 0.038), tumor size (p = 0.025), Gleason grade (p = 0.051) and PSA (p = 0.032). In univariate analysis miR-141 (TE + TS) was significantly associated with biochemical failure-free survival (BFFS, p = 0.007) and clinical failure-free survival (CFFS, p = 0.021). For miR-145, there were no differences between patients with high versus low expression. In multivariate analysis overexpression of miR-141 in tumor epithelium and tumor stroma was significantly associated with BFFS (HR = 1.07 CI95% 1.00-1.14, p = 0.007). To conclude, high expression of miR-141 appears associated with increased risk of biochemical PC recurrence.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje